This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Tuesday's Financial Winners & Losers

New York Stock Exchange (NYX) fell again Tuesday as the exchange edged ever closer to its imminent $14 billion merger with Europe's Euronext exchange. Shares were losing $2.63, or 2.6%, to $94.37.

Nelnet (NNI - Get Report) rose after an analyst with J.P. Morgan Chase reiterated his overweight rating on the student lender. The stock fell Friday after the company lost a lucrative contract with the Canadian government. The analyst, however, says Nelnet is likely to gain market share from the Federal Family Education Loan Program business. Shares were up $1.17, or 4.3%, to $27.82.

Medical Properties Trust (MPW - Get Report) continued to rise after an analyst with Robert W. Baird began his coverage on the real estate investment trust late last week with a buy rating. The REIT specializes in investing in health care facilities. Shares were climbing 25 cents, or 1.7%, to $15.06.

State Bancorp (STBC) was still rising after Friday's announcement that the New York bank had raised more than $36 million in a 2.3 million share private placement. Shares were up 41 cents, or 2.1%, to $19.76.

Brookfield Properties (BPO) slipped again following the news that the underwriters of its recent $1.14 billion stock offering have exercised their over-allotment option. Late last week the property management company said the underwriters were buying an additional 1.9 million of its shares at a price of $38 apiece. Shares were down 9 cents to $38.20.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs